Whole cell melanoma vaccine genetically modified to stem cells like phenotype generates specific immune responses to ALDH1A1 and long-term survival in advanced melanoma patients

References

• Mackiewicz J, Mackiewicz A. Programmed cell death 1 checkpoint inhibitors in the treatment of patients with advanced melanoma. Contemp Oncol (Pozn). 2017;21(1):1–5. doi:10.5114/wo.2017.66651.
   PubMed Web of Science ®Google Scholar
• Noman MZ, Hasmim M, Messai Y, Terry S, Kieda C, Janji B, Chouaib S. Hypoxia: a key player in antitumor immune response. A review in the theme: cellular responses to hypoxia. Am J Physiol Cell Physiol. 2015;309(9):C569–79. doi:10.1152/ajpcell.00207.
   PubMed Web of Science ®Google Scholar
• Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105–111. doi:10.1038/35102167.
   PubMed Web of Science ®Google Scholar
• Kwiatkowska-Borowczyk EP, Gąbka-Buszek A, Jankowski J, Mackiewicz A. Immunotargeting of cancer stem cells. Contemp Oncol (Pozn). 2015;19(1A):A52–9. doi:10.5114/wo.2014.47129.
   PubMedGoogle Scholar
• Wiznerowicz M, Fong AC, Mackiewicz A, Hawley RC. Development of dicistronic double copy retroviral vectors for human gene therapy. Gene Ther. 1997;4:1061–1068. doi:10.1007/978-1-4615-5357-1_68.
   PubMed Web of Science ®Google Scholar
• Fisher M, Goldschmitt J, Peschel C, Brakenhoff JP, Kallen KJ, Wollmer A, Grotzinger J, Rose-John S. A bioactive designer cytokine for human hematopoietic progenitor cell expansion. Nat Biotechnol. 1997;15:142–145. doi:10.1038/nbt0297-142.
   PubMed Web of Science ®Google Scholar
• Kozłowska A, Mackiewicz J, Mackiewicz A. Therapeutic gene modified cell based cancer vaccines. Gene. 2013;525(2):200–207. doi:10.1016/j.gene.2013.03.056.
   PubMed Web of Science ®Google Scholar
• Mackiewicz J, Karczewska-Dzionk A, Laciak M, Kapcinska M, Wiznerowicz M, Burzykowski T, Zakowska M, Rose-John S, Mackiewicz A. Whole cell therapeutic vaccine modified with Hyper-IL6 for combinational treatment of nonresected advanced melanoma. Medicine (Baltimore). 2015;94(21):e853. doi:10.1097/MD.0000000000000853.
   PubMed Web of Science ®Google Scholar
• Mackiewicz A, Mackiewicz J, Wysocki PJ, Wiznerowicz M, Kapcinska M, Laciak M, Rose-John S, Izycki D, Burzykowski T, Karczewska-Dzionk A. Long-term survival of high-risk melanoma patients immunized with a Hyper-IL-6-modified allogeneic whole-cell vaccine after complete resection. Expert Opin Investig Drugs. 2012;21(6):773–783. doi:10.1517/13543784.2012.684753.
   PubMed Web of Science ®Google Scholar
• Islam M, Sharma S, Teknos TN. RhoC regulates cancer stem cells in head and neck squamous cell carcinoma by overexpressing IL-6 and phosphorylation of STAT3. PLoS One. 2014;9:e88527. doi:10.1371/journal.pone.0088527.
   PubMed Web of Science ®Google Scholar
• Yuan J, Zhang F, Niu R. Multiple regulation pathways and pivotal biological functions of STAT3 in cancer. Sci Rep. 2015;5:176. doi:10.1038/srep17663.
   Web of Science ®Google Scholar
• Teng Y, Ross JL, Cowell JK. The involvement of JAK-STAT3 in cell motility, invasion, and metastasis. JAKSTAT. 2014;3(1):e28086. doi:10.4161/jkst.28086.
   PubMedGoogle Scholar
• Drucker C, Gewiese J, Malchow S, Scheller J, Rose-John S. Impact of interleukin-6 classic- and trans-signaling on liver damage and regeneration. J Autoimmun. 2010;34(1):29–37. doi:10.1016/j.jaut.2009.08.003.
   PubMed Web of Science ®Google Scholar
• Mackiewicz A, Schoolting H, Heinrich PC, Rose-John S. Complex of soluble human IL-6-receptor/IL-6 up-regulates expression of acute phase proteins. J Immunol. 1992;149:2021–2027.
   PubMed Web of Science ®Google Scholar
• Rose-John S. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci. 2012;8:1237–1247. doi:10.7150/ijbs.4989.
   PubMed Web of Science ®Google Scholar
• Bottcher JP, Schranz O, Garbes C, Zaremba A, Hegenbarth S, Kurts C, Beyer M, Schultze JL, Kastenmüller W, Rose-John S, et al. IL-6 trans-signaling-dependent rapid development of cytotoxic T cell function. Cell Rep. 2014;8:1318–1327. doi:10.1016/j.celrep.2014.07.008.
   PubMed Web of Science ®Google Scholar
• Ozbek S, Peters M, Breuhahn K, Mann A, Blessing M, Fischer M, Schirmacher P, Mackiewicz A, Rose-John S. The designer cytokine hyper-IL-6 mediates growth inhibition and GM-CSF-dependent rejection of B16 melanoma cells. Oncogene. 2001;20(8):972–979. doi:10.1038/sj.onc.1204180.
   PubMed Web of Science ®Google Scholar
• Dominitzki S, Fantini MC, Neufert C, Nikolaev A, Galle PR, Scheller J, Monteleone G, Rose-John S, Neurath MF, Becker C. Cutting edge: trans-signaling via the soluble IL-6R abrogates the induction of FoxP3 in Naive CD4+CD25- T cells. J Immunol. 2007;179:2041–2045. doi:10.4049/jimmunol.179.4.2041.
   PubMed Web of Science ®Google Scholar
• Visus C, Ito D, Amoscato A, Maciejewska-Franczak M, Abdelsalem A, Dhir R, Shin DM, Donnenberg VS, Whiteside TL, DeLeo AB. Identification of human aldehyde dehydrogenase 1 family member A1 as a novel CD8+ T-cell derived tumor antigen in squamous cell carcinoma of the head and neck. Cancer Res. 2007;67:10538–10545. doi:10.1158/0008-5472.CAN-07-1346.
   PubMed Web of Science ®Google Scholar
• Visus C, Wang Y, Lozano-Leon A, Ferris RL, Silver S, Szczepanski MJ, Brand RE, Ferrone CR, Whiteside TL, Ferrone S, et al. Targeting ALDHbright human carcinoma-initiating cells with ALDH1-specific CD8+ T cells. Clin Cancer Res. 2011:17-6174-84. doi:10.1158/1078-0432.CCR-11-1111.
   Web of Science ®Google Scholar
• Luo Y, Dallaglio K, Chen Y, Robinson WA, Robinson SE, McCarter MD, Wang J, Gonzalez R, Thompson DC, Norris DA, et al. ALDH1A1 isozymes are markers of human melanoma stem cells and targets for therapy. Stem Cells. 2012;10:2100–2113. doi:10.1002/stem.1193.
   Web of Science ®Google Scholar
• Yue L, Huang Z-M, Fong S, Leong S, Jakowatz JG, Charruyer-Reinwald A, Wei M, Ghadially R. Targeting ALDH1 to decrease tumorigenicity, growth, and metastases of human melanoma. Melanoma Res. 2015;25:138–148. doi:10.1097/CMR.0000000000000144.
   PubMed Web of Science ®Google Scholar
• Lu L, Tao H, Chang AE, Hu Y, Shu G, Chen Q, Egenti M, Owen J, Moyer MEP, Huang S, et al. Cancer stem cell vaccine inhibits metastases of primary tumors and induces humoral immune responses against cancer stem cells. Oncoimmunology. 2015;4(3):e990767. doi:10.4161/2162402X.2014.990767.
   PubMed Web of Science ®Google Scholar
• Taylor LA, Abraham RM, Tahirovic E, van Belle P, Li B, Huang L, Elder DE, Gimotty P, Xu X. High ALDH1 expression correlated with a better prognosis of malignant melanoma. Mod Pathol. 2017;30(5):634–639. doi:10.1038/modpathol.2016.226.
   PubMed Web of Science ®Google Scholar
• Nawrocki S, Mackiewicz A. Clinical trials of active cancer immunotherapy. Expert Opin Investig Drugs. 2007;16:1137–1141. doi:10.1517/13543784.16.8.1137.
   PubMed Web of Science ®Google Scholar
• Mackiewicz J, Mackiewicz A. Design of clinical trials for therapeutic cancer vaccines development. Eur J Pharmacol. 2009;625(1–3):84–89. doi:10.1016/j.ejphar.2009.09.069.
   PubMed Web of Science ®Google Scholar
• Schaefer C, Butterfield LH, Lee S, Kim GG, Visus C, Albers A, Kirkwood JM, Whiteside TL. Function but not phenotype of melanoma peptide-specific CD8+ T cells correlate with survival in a multipeptide vaccine trial (ECOG 1696). Int J Cancer. 2012;131:874–884. doi:10.1002/ijc.26481.
   PubMed Web of Science ®Google Scholar
• Keskinov AA, Shurin MR. Myeloid regulatory cells in tumor spreading and metastasis. Immunobiology. 2015;220:236–242. doi:10.1016/j.imbio.2014.07.017.
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9:162–174. doi:10.1038/nri2506.
   PubMed Web of Science ®Google Scholar
• Marigo I, Dolcetti L, Serafini P, Zanovello P, Bronte V. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev. 2008;222:162–179. doi:10.1111/j.1600-065X.2008.00602.x.
   PubMed Web of Science ®Google Scholar
• Kapanadze T, Gamrekelashvili J, Ma C, Chan C, Zhao F, Hewitt S, Zender L, Kapoor V, Felsher DW, Manns MP, et al. Regulation of accumulation and function of myeloid-derived suppressor cells in different murine models of hepatocellular carcinoma. J Hepatol. 2013;59:1007–1013. doi:10.1016/j.jhep.2013.06.010.
   PubMed Web of Science ®Google Scholar
• Mace TA, Ameen Z, Collins A, Wojcik S, Mair M, Young GS, Fuchs JR, Eubank TD, Frankel WL, Bekaii-Saab T, et al. Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner. Cancer Res. 2013;73:3007–3018. doi:10.1158/0008-5472.CAN-12-4601.
   PubMed Web of Science ®Google Scholar
• Filipazzi P, Huber V, Rivoltini L. Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. Cancer Immunol Immunother. 2012;61:255–263. doi:10.1007/s00262-011-1161-9.
   PubMed Web of Science ®Google Scholar
• Lu T, Ramakrishnan R, Altiok S, Youn JI, Cheng P, Celis E, Pisarev V, Sherman S, Sporn MB, Gabrilovich D. Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice. J Clin Invest. 2011;121:4015–4029. doi:10.1172/JCI45862.
   PubMed Web of Science ®Google Scholar
• Huang A, Zhang B, Wang B, Zhang F, Fan KX, Guo YJ. Increased CD14(+)HLA-DR (-/low) myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients. Cancer Immunol Immunother. 2013;62:1439–1451. doi:10.1007/s00262-013-1450-6.
   PubMed Web of Science ®Google Scholar
• Choi J, Suh B, Ahn YO, Kim TM, Lee JO, Lee SH, Heo DS. CD15+/CD16low human granulocytes from terminal cancer patients: granulocytic myeloid-derived suppressor cells that have a suppressive function. Tumour Biol. 2012;33:121–129. doi:10.1007/s13277-011-0254-6.
   PubMedGoogle Scholar
• Gabitass RF, Annels NE, Stocken DD, Pandha HA, Middleton GW. Elevated myeloid-derived suppressor cells in the pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother. 2011;60:1419–1430. doi:10.1007/s00262-011-1028-0.
   PubMed Web of Science ®Google Scholar
• Solito S, Falisi E, Diaz-Montero CM, Doni A, Pinton L, Rosato A, Francescato S, Basso G, Zanovello P, Onicescu G, et al. A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood. 2011;118:2254–2265. doi:10.1182/blood-2010-12-325753.
   PubMed Web of Science ®Google Scholar
• Mundy-Bosse BL, Young GS, Bauer T, Binkley E, Bloomston M, Bill MA, Bekaii-Saab T, Carson WE 3rd, Lesinski GB. Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4⁺ T cells from patients with GI malignancy. Cancer Immunol Immunother. 2011;60:1269–1279. doi:10.1007/s00262-011-1029-z.
   PubMed Web of Science ®Google Scholar
• Poschke I, Mao Y, Adamson L, Salazar-Onfray F, Masucci G, Kiessling R. Myeloid-derived suppressor cells impair the quality of dendritic cell vaccines. Cancer Immunol Immunother. 2012;61:827–838. doi:10.1007/s00262-011-1143-y.
   PubMed Web of Science ®Google Scholar
• Filipazzi P, Valenti R, Huber V, Pilla L, Canese P, Iero M, Castelli C, Mariani L, Parmiani G, Rivoltini L. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol. 2007;25:2546–2553. doi:10.1200/JCO.2006.08.5829.
   PubMed Web of Science ®Google Scholar
• Mandruzzato S, Solito S, Falisi E, Francescato S, Chiarion-Sileni V, Mocellin S, Zanon A, Rossi CR, Nitti D, Bronte V, et al. IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients. J Immunol. 2009;182:6562–6568. doi:10.4049/jimmunol.0803831.
   PubMed Web of Science ®Google Scholar
• Schilling B, Sucker A, Griewank K, Zhao F, Weide B, Görgens A, Giebel B, Schadendorf D, Paschen A. Vemurafenib reverses immunosuppression by myeloid-derived suppressor cells. Int J Cancer. 2013;133:1653–1663. doi:10.1002/ijc.28168.
   PubMed Web of Science ®Google Scholar
• Umansky V, Sevko A, Gebhardt C, Utikal J. Myeloid-derived suppressor cells in malignant melanoma. J Dtsch Dermatol Ges. 2014;12:1021–1027. doi:10.1111/ddg.12411.
   PubMed Web of Science ®Google Scholar
• Rudolph BM, Loquai C, Gerwe A, Bacher N, Steinbrink K, Grabbe S, Tuettenberg A. Increased frequencies of CD11b(+) CD33(+) CD14(+) HLA-DR(low) myeloid-derived suppressor cells are an early event in melanoma patients. Exp Dermatol. 2014;23:202–204. doi:10.1111/exd.12336.
   PubMed Web of Science ®Google Scholar
• Jordan KR, Amaria RN, Ramirez O, Callihan EB, Gao D, Borakove M, Manthey E, Borges VF, McCarter MD. Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients. Cancer Immunol Immunother. 2013;62:1711–1722. doi:10.1007/s00262-013-1475-x.
   PubMed Web of Science ®Google Scholar
• Chevolet I, Speeckaert R, Schreuer M, Neyns B, Krysko O, Bachert C, Van Gele M, Van Geel N, Brochez L. Clinical significance of plasmacytoid dendritic cells and myeloid-derived suppressor cells in melanoma. J Transl Med. 2015;13:9. doi:10.1186/s12967-014-0376-x.
   PubMed Web of Science ®Google Scholar
• Antonia SJ, Mirza N, Fricke I, Chiappori A, Thompson P, Williams N, Bepler G, Simon G, Janssen W, Lee J-H, et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res. 2006;12:878–887. doi:10.1158/1078-0432.CCR-05-2013.
   PubMed Web of Science ®Google Scholar
• Iclozan C, Antonia S, Chiappori A, Chen DT, Gabrilovich D. Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer. Cancer Immunol Immunother. 2013;62:909–918. doi:10.1007/s00262-013-1396-8.
   PubMed Web of Science ®Google Scholar
• Ramachandran H, Laux J, Moldovan I, Caspell R, Lehmann PV, Subbramanian RA. Optimal thawing of cryopreserved peripheral blood mononuclear cells for use in high-throughput human immune monitoring studies. Cells. 2012;1(3):313–324. doi:10.3390/cells1030313.
   PubMedGoogle Scholar